Altimmune (NASDAQ:ALT - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Altimmune to post earnings of ($0.36) per share and revenue of $0.00 million for the quarter.
Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Altimmune Stock Down 4.8 %
NASDAQ:ALT traded down $0.26 during mid-day trading on Tuesday, reaching $5.17. 1,046,100 shares of the company were exchanged, compared to its average volume of 2,847,904. Altimmune has a 12 month low of $3.55 and a 12 month high of $11.16. The company has a fifty day moving average of $5.15 and a 200 day moving average of $6.64. The stock has a market cap of $398.16 million, a PE ratio of -3.36 and a beta of 1.13.
Insider Activity at Altimmune
In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of equities analysts have issued reports on ALT shares. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. Stifel Nicolaus initiated coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $20.83.
Get Our Latest Stock Analysis on Altimmune
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Further Reading

Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.